DeCode's new offering adds to an ongoing controversy over whether people in the island country have a right to know if they are at increased risk for disease.
CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.
The FDA will consider the companion diagnostic application alongside data for Pfizer's talazoparib in BRCA-mutated advanced breast cancer.
The Center for Genomic Interpretation and NSGC want payors to cover confirmatory testing for patients with positive results from 23andMe's FDA-cleared test.
The funding will be available to members of the Association of Community Cancer Centers, a cancer care provider advocacy group.
A Phase III randomized trial uncovered enhanced carboplatin response in advanced triple-negative breast cancer patients with germline mutations affecting BRCA1/2.
Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.
23andMe's Anne Wojcicki writes in an opinion piece at Stat News that people can understand their genetic risk information without the input of experts.
There's an increase in genetic testing for breast cancer risk in Northern Ireland, BBC News reports, adding that better support for those tested is also needed.
The 4,000-participant study will use a digital enrollment platform and will provide free genetic testing as well as support from doctors and genetics experts.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.